TheStreet Ratings

10 Best Life Sciences Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 life sciences stocks are rated highest by our methodology.

Equity Top: Life Sciences Tools & Services

Source: TheStreet Ratings

Best Investments for

Life Sciences

The health plan crafted by Republican lawmakers would increase the number of people without health coverage by 14 million from today's coverage level in 2018.
5/24/17 5:24PM
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
5/24/17 9:29AM
An FDA advisory panel is reviewing Puma's breast cancer drug neratinib.
5/24/17 7:41AM
The biopharmaceutical firm on Tuesday announced changes, including the planned departure of its chief financial officer.
5/23/17 5:50PM
The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
5/23/17 4:05PM
The dividend will be paid on July 10 to shareholders of record at the close of business on June 15.
5/23/17 2:57PM
The analysis was conducted by the Data and Safety Monitoring Board (DSMB) which found no safety concerns and recommended continuation of enrollment without modification in a trial.
5/23/17 12:46PM
The biopharmaceutical firm's CFO announced today that he will be leaving in August.
5/23/17 12:24PM
Cerus, Alexion Pharmaceuticals and NantKwest were among the biotech movers in premarket trading on Tuesday.
5/23/17 9:29AM
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF , we found that the implied analyst target price for the ETF based upon its underlying holdings is $91.44 per unit.
5/23/17 9:12AM
Merck & Co may face financial penalties from U.K. regulators after the Competition & Markets Authority released provisional findings of a drug pricing investigation into the American drugmaker.
5/23/17 6:05AM
AstraZeneca shares edged higher Tuesday as investors shrugged off a mixed set of phase-3 results for the Anglo Swedish drug maker's Bydureon Exscel type II diabetes treatment.
5/23/17 4:14AM
European stocks are expected to open modestly higher Tuesday even in the weak of a deadly terrorist atrocity which left nineteen dead and nearly sixty injured in Manchester.
5/23/17 1:56AM
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
5/22/17 6:29PM